Next-generation tau tracers might prove to be more useful for tracking in vivo PSP pathology progression because of a combination of good affinity for 4-repeat tau and lower off-target binding to monoamine oxidases (i.e., 18F-PI-2620 (24)). This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.